In November 2021, Riverside Australia Fund III completed the acquisition of Avance Clinical, Australia’s largest full-service Contract Research Organisation (CRO)
specialising in delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs.
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient, has been providing CRO services in the region for the past 24 years. The company’s clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. Avance Clinical offers pre-clinical services with their experienced ClinicReady team, right through to Phase 1 and 2 trials leveraging significant Government incentive rebates and rapid start-up regulatory processes.
With experience across more than 105 indications the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review. Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. As a company, Avance Clinical has focused on state-of-the-art technology and systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of Avance Clinical’s trusted technology partners.
